Document is current
Any future updates will be listed below
-
Authors
Chan, Hilary
Savoie, Marissa B.
Munir, Amir
Moslehi, Javid
Anwar, Mekhail
Laffan, Angela
Rowen, Tami
Salmon, Rebeca
Varma, Madhulika
Van Loon, Katherine
- License Information
-
More Information
Article History
Accepted: 11 November 2022
First Online: 9 January 2023
Declarations
:
: Not applicable to this manuscript.
: Not applicable to this manuscript.
: Not applicable to this manuscript.
: JM has served as a consultant for Novartis, Pfizer, Bristol-Myers Squibb, Takeda, Acceleron, Vertex, Incyte, Rgenix, Verastem, Pharmacyclics, StemCentRx, Heat Biologics, Daiichi Sankyo, Regeneron, Myokardia, Redux, Audentes Pharmaceuticals, AstraZeneca, Deciphera, Ipsen, Intrexon, GlaxoSmithKline, Myovant, Boehringer, Cytokinetics, Mallinckrodt Pharmaceuticals, ProteinCure, Star Therapeutics, Aerovate Therapeutics, Silverback Therapeutics, Kurome Therapeutics, Beigene, Antev Ltd, LapCorp, Kiniksa, Prelude Therapeutics, TransThera Sciences, and Voyager Therapeutics. JM is supported by funding from the NIH (R01HL141466, R01HL155990, R01HL156021, R01 HL160688). All other authors do not report related financial interests to disclose.
